Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Anti-tumor monoclonal antibodies

Nitta, T, Yagita, H., Azuma, T., Sato, K, and Okomura, K (1989) F(ab )2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells. Eur. J. Immunol. 19, 1437-1441... [Pg.133]

M. Driscoll, R. Hcuisen, C. Ding, D.E. Cramer, J. Yan, Therapeutic potential of various P-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biology Therapy, 8 (3), 216-223, 2009. [Pg.100]

Ixwis, G.D., I. Figari, B. Fendly, W.L. Wong, P. Carter, C. Gorman, and H.M. Shepard, Differential responses of human tumor cell lines to anti-pl85HER2 monoclonal antibodies. Cancer Immunol Immunother, 1993.37(4) 255-63. [Pg.400]

Sarup, J. C., Johnson, R. M., King, K. L., Fendly, B. M., Lipari, M. T., Napier, M. A., Ullrich, A., and Shepard, H. M. (1991). Characterization of an anti-pl85HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1, 72-82. [Pg.418]

Gauchat, J.F., Aversa, G., Gascan, H. and De-Vries, J.E. (1992a). Modulation of IL-4 induced germline epsilon RNA synthesis in human B cells by tumor necrosis factor-alpha, anti-CD40 monoclonal antibodies or transforming growth factor-beta correlates with levels of IgE production. Int. Immunol. 4, 397-406. [Pg.48]

Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden clinical and molecular evaluation. Blood 2001 97 101-106. [Pg.2465]

Samp JC, Johnson RM, King KL, et al. Characterization of an anti-pl85HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Reg 1991,... [Pg.160]

Alegre M, Vandenabeele P, Flamand V, Moser M, Leo O, Abramowicz D, Urbain J, Piers W, Goldman M. Elypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice role of tumor necrosis factor. Eur J Immunol 1990 20(3) 707-710. [Pg.479]

Mordenti, J. et al.. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans, Toxicol. Pathol., 27 14-21, 1999. [Pg.71]

See other pages where Anti-tumor monoclonal antibodies is mentioned: [Pg.237]    [Pg.237]    [Pg.269]    [Pg.506]    [Pg.573]    [Pg.367]    [Pg.168]    [Pg.113]    [Pg.460]    [Pg.136]    [Pg.198]    [Pg.254]    [Pg.18]    [Pg.136]    [Pg.45]    [Pg.643]    [Pg.653]    [Pg.182]    [Pg.11]    [Pg.393]    [Pg.30]    [Pg.98]    [Pg.2535]    [Pg.151]    [Pg.501]    [Pg.1277]    [Pg.1714]    [Pg.128]    [Pg.425]    [Pg.157]    [Pg.18]    [Pg.344]    [Pg.168]    [Pg.262]    [Pg.321]    [Pg.324]    [Pg.330]    [Pg.30]    [Pg.98]   


SEARCH



Anti antibodies

Anti-tumor

Anti-tumoral

Monoclonal anti

Tumors monoclonal antibodies

© 2024 chempedia.info